Innoviva Operating Income 2010-2023 | INVA
Innoviva operating income from 2010 to 2023. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Innoviva Annual Operating Income
(Millions of US $) |
| 2023 |
$114 |
| 2022 |
$474 |
| 2021 |
$375 |
| 2020 |
$321 |
| 2019 |
$246 |
| 2018 |
$238 |
| 2017 |
$184 |
| 2016 |
$109 |
| 2015 |
$32 |
| 2014 |
$-34 |
| 2013 |
$-29 |
| 2012 |
$-25 |
| 2011 |
$-110 |
| 2010 |
$-78 |
| 2009 |
$-81 |
Innoviva Quarterly Operating Income
(Millions of US $) |
| 2023-12-31 |
$38 |
| 2023-09-30 |
$18 |
| 2023-06-30 |
$29 |
| 2023-03-31 |
$30 |
| 2022-12-31 |
$24 |
| 2022-09-30 |
$289 |
| 2022-06-30 |
$83 |
| 2022-03-31 |
$78 |
| 2021-12-31 |
$105 |
| 2021-09-30 |
$95 |
| 2021-06-30 |
$97 |
| 2021-03-31 |
$79 |
| 2020-12-31 |
$85 |
| 2020-09-30 |
$84 |
| 2020-06-30 |
$76 |
| 2020-03-31 |
$76 |
| 2019-12-31 |
$74 |
| 2019-09-30 |
$61 |
| 2019-06-30 |
$60 |
| 2019-03-31 |
$52 |
| 2018-12-31 |
$77 |
| 2018-09-30 |
$58 |
| 2018-06-30 |
$63 |
| 2018-03-31 |
$41 |
| 2017-12-31 |
$66 |
| 2017-09-30 |
$40 |
| 2017-06-30 |
$48 |
| 2017-03-31 |
$29 |
| 2016-12-31 |
$38 |
| 2016-09-30 |
$28 |
| 2016-06-30 |
$26 |
| 2016-03-31 |
$18 |
| 2015-12-31 |
$17 |
| 2015-09-30 |
$8 |
| 2015-06-30 |
$5 |
| 2015-03-31 |
$1 |
| 2014-12-31 |
$0 |
| 2014-09-30 |
$-10 |
| 2014-06-30 |
$-10 |
| 2014-03-31 |
$-15 |
| 2013-12-31 |
$19 |
| 2013-09-30 |
$-8 |
| 2013-06-30 |
$-7 |
| 2013-03-31 |
$-33 |
| 2012-12-31 |
$-30 |
| 2012-09-30 |
$-33 |
| 2012-06-30 |
$-36 |
| 2012-03-31 |
$86 |
| 2011-12-31 |
$-36 |
| 2011-09-30 |
$-29 |
| 2011-06-30 |
$-24 |
| 2011-03-31 |
$-21 |
| 2010-12-31 |
$-18 |
| 2010-09-30 |
$-20 |
| 2010-06-30 |
$-19 |
| 2010-03-31 |
$-21 |
| 2009-12-31 |
$-21 |
| 2009-09-30 |
$-21 |
| 2009-06-30 |
$-21 |
| 2009-03-31 |
$-18 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$0.945B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
